Effects of molecular size and chemical structure on renal and hepatic removal of exogenously administered chondroitin sulfate in rats

Biochimica et Biophysica Acta - General Subjects

Volumn 1760, Issue 6, 2006, Pages 865-876

  Pecly, Inah M D ^a   Melo Filho, Nelson M ^a   Mourão, Paulo A S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Glycosaminoglycan; Plasma level; Renal filtration; Sulfated polysaccharide; Tissue accumulation

Indexed keywords

CARBOXYL GROUP; CHONDROITIN SULFATE; GLUCURONIC ACID; GLYCOSAMINOGLYCAN; HYALURONIDASE; SULFATE; SULFUR 35;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIGESTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; DRUG URINE LEVEL; GLOMERULUS FILTRATION; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MOLECULAR SIZE; MOLECULE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHICK EMBRYO; CHONDROITIN SULFATES; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; GLUCURONIC ACID; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY; LIVER; MALE; MOLECULAR WEIGHT; OXIDATION-REDUCTION; RATS; RATS, WISTAR; SULFUR RADIOISOTOPES;

MAMMALIA;

EID: 33744804253     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2005.11.009     Document Type: Article

References (43)

1. Mourão P.A.S. Distribution of chondroitin 4-sulfate and chondroitin 6-sulfate in human articular and growth cartilage. Arthritis Rheum. 31 (1988) 1028-1033
2. Harab R.C., and Mourão P.A.S. Increase of chondroitin 4-sulfate concentration in the endochondral ossification cartilage of normal dogs. Biochim. Biophys. Acta 992 (1989) 237-240
3. In: Varki A., Cummings R., Esko J., Freeze H., Hart G., and Marth J. (Eds). Degradation and Turnover of Glycans, in: Essentials of Glycobiology (1999), Cold Spring Harbor Laboratory Press, Cold Spring Harbor 267-283
4. Morrison L.M., Bajwa G.S., Alfin-Slater R.B., and Ershoff B.H. Prevention of vascular lesions by chondroitin sulfate A in the coronary artery and aorta of rats induced by a hypervitaminosis D, cholesterol-containing diet. Atherosclerosis 16 (1972) 105-118
5. Morrison L.M., Murata K., Quilligan J.J., Schjeide A.O., and Freeman L. Prevention of atherosclerosis in sub-human primates by chondroitin sulfate. Circ. Res. 19 (1966) 358-363
6. Morrison L.M., Quilligan J.J., Murata K., Schjeide A.O., Freeman L., and Ershoff B.H. Treatment of atherosclerosis with acid mucopolysaccharides. Exp. Med. Surg. 25 (1967) 61-71
7. Morrison L.M., Branwood A.W., Ershoff B.H., Murata K., Quilligan J.J., Schjeide O.A., Patek P., Berenik S., Freeman L., Dunn O.J., and Rucker P. The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: preliminary report. Exp. Med. Surg. 27 (1969) 278-289
8. Uebelhart D., Malaise M., Marcolongo R., DeVathariell F., Piperno M., Mailleux E., Fiovaranti A., Matoso L., and Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-bind, multicenter study versus placebo. Osteoarthritis Cart. 12 (2004) 269-276
9. Rovetta G., Monteforte P., Molfetta G., and Balestra V. A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Exp. Clin. Res. 30 (2004) 11-16
10. Ito M., Baba M., Sato A., Pauwels R., De Clercq E., and Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of immunodeficiency virus (HIV) in vitro. Antiviral Res. 7 (1987) 361-367
11. Abrams D.I., Kuno S., Wong R., Jeffords K., Nash M., Molaghan R.N., Gorter R., and Ueno R. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann. Intern. Med. 110 (1989) 183-188
12. Gambaro G., Venturini A.P., Noonan D.M., Fries W., Re G., Garbisa S., Milanesi C., Pesarini A., Borsatti A., Marchi E., and Baggio B. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 46 (1994) 797-806
13. Tostes V., Martinusso C.A., Werneck C.C.C., Mourão P.A.S., and Cardoso L.R. Low-molecular-weight dextran sulfate prevents experimental urolithiasis in rats. Clin. Chim. Acta 341 (2004) 147-155
14. Hirsh J., Warkentin E.T., Granger C., Ohman E.M., and Dalen J.E. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114 (1998) 4895-5105
15. Mourão P.A.S., Guimarães M.A.M., Mulloy B., Thomas S., and Gray E. Antithrombotic activity of a fucosylated chondroitin sulphate from echinoderm: sulphated fucose branches on the polysaccharide account for its antithrombotic action. Br. J. Haematol. 101 (1998) 647-652
16. Pacheco R.G., Vicente C.P., Zancan P., and Mourão P.A.S. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coagul. Fibrinolysis 11 (2000) 563-573
17. Vicente C.P., Zancan P., Peixoto L.L., Alves-Sá R., Araújo F.S., Mourão P.A.S., and Pavão M.S.G. Unbalanced effects of dermatan sulfate with different sulfation patterns on coagulation, thrombosis and bleeding. Thromb. Haemost. 86 (2001) 1215-1220
18. Zancan P., and Mourão P.A.S. Venous and arterial thrombosis in rat models: dissociation of the antithrombotic effects of glycosaminoglycans. Blood Coagul. Fibrinolysis 15 (2004) 45-54
19. Verges J., Montell E., Herrero M., Perna C., Cuevas J., Perez M., and Moller I. Clinical and histophatological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. Dermatol. Online J. 11 (2005) 31
20. Michel B.A., Stucki G., Frey D., De Valthaire F., Vignon E., Bruehlmann P., and Uebelhart D. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 52 (2005) 779-786
21. Kandrotas R.J. Heparin pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 22 (1992) 359-374
22. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 188S-203S
23. Laurent T.C., Fraser J.R., Pertoft H., and Smedsrod B. Binding of hyaluronate and chondroitin sulphate to liver endothelial cells. Biochem. J. 243 (1986) 653-658
24. Zhou B., Weigel J.A., Fauss L., and Weigel P.H. Identification of the hyaluran receptor for endocytosis (HARE). J. Biol. Chem. 275 (2000) 37733-37741
25. Weigel J.A., and Weigel P.H. Characterization of the recombinant rat 175-kDa hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. 278 (2003) 42802-42811
26. Zhou B., McGary C.T., Weigel J.A., Saxena A., and Weigel P.H. Purification and molecular identification of the human hyaluronan receptor for endocytosis. Glycobiology 13 (2003) 339-349
27. Vieira R.P., and Mourão P.A.S. Occurrence of a unique fucose-branched chondroitin sulfate in the body wall of a sea cucumber. J. Biol. Chem. 263 (1988) 18176-18183
28. Farndale R.W., Buttle D.J., and Barret A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta 883 (1986) 173-177
29. Werneck C.C., Cruz M.S., Silva L.C.F., Villa-Verde D.M.S., Savino W., and Mourão P.A.S. Is there a glycosaminoglycan-related heterogeneity of the thymic-epithelium?. J. Cell. Physiol. 185 (2000) 68-79
30. Taylor R.L., Shively J.E., and Conrad H.E. Stoichiometric reduction of uronic acid carboxyl groups in polysaccharides. Methods Carbohydr. Chem. 7 (1996) 149-151
31. Bitter T., and Muir H.M. A modified uronic acid carbazole reaction. Anal. Biochem. 4 (1962) 330-334
32. Ivarsson L., Appelgren L., and Rudenstam C.M. Plasma volume after dextran infusion in rats sensitive and non-sensitive to dextran. Eur. Surg. Res. 7 (1975) 315-325
33. Hirsh J., and Levine M.N. Low molecular weight heparin. Blood 79 (1992) 1-18
34. Weitz J.I. Low-molecular-weight-heparins. N. Engl. J. Med. 337 (1997) 688-698
35. Conrad H.E. Heparin-Binding Proteins (1998), Academic Press, San Diego 170-171
36. Lima C.R., Aguiar J.A.K., and Michelacci Y.M. Reduced urinary excretion of sulfated polysaccharides in diabetic rats. Biochim. Biophys. Acta 1741 (2005) 30-41
37. Guimarães M.A.M., and Mourão P.A.S. Urinary excretion of sulfated polysaccharides administered to Wistar rats suggests a renal permselectivity to these polymers base on molecular size. Biochim. Biophys. Acta 1335 (1997) 161-172
38. Diamond J.R., and Karnovsky M.J. Non-anticoagulant protective effect of heparin in chronic aminonucleoside nephrosis. Renal Physiol. 9 (1986) 366-374
39. Ceol M., Vianello D., Schleicher E., Anglani F., Barbantini M., Bonfante L., Bertaglia G., Graziotto R., D'Angelo A., Del Prete D., and Gambaro G. Heparin reduces glomerular infiltration and TGF-β protein expression by macrophages in puromicin glomerulosclerosis. J. Nephrol. 16 (2003) 210-218
40. Hirsh J. Overview of low molecular weight heparins and heparinoids: basic and clinical aspects. Aust. N. Z. J. Med. 22 (1992) 487-495
41. Mourão P.A.S., Kato S., and Donnelly P.V. Spondyloepiphyseal dysplasia, chondroitin sulfate type: a possible defect of PAPS-chondroitin sulfate sulfotransferase in humans. Biochem. Biophys. Res. Commun. 98 (1981) 388-396
42. Coscarelli P.G., and Mourão P.A.S. Shift in the distribution of isomeric chondroitin 4- and 6-sulfate in human urine with age. Biomed. Mol. Med. 54 (1995) 146-147
43. Pereira D.A., Aguiar J.A., Hagiwara M.K., and Michelacci Y.M. Changes in cat urinary glycosaminoglycans with age and in feline urologic syndrome. Biochim. Biophys. Acta 1672 (2004) 1-11